MST1 and neoplasm: Targeting the core kinases of the Hippo signaling pathway, MST1/2 and LATS1/2, to activate YAP and TAZ activity could be desirable in regenerative medicine and in certain hematologic malignancies where YAP functions as a tumor suppressor.